The settlement resolves all outstanding U.S. lawsuits over Xarelto. Plaintiffs in the lawsuits claimed the blood thinner causes uncontrollable and irreversible bleeding and said the drugmakers failed to adequately warn of that risk.
Under the settlement agreement, each drugmaker will pay half. Neither company admits wrongdoing under the agreement.
Bayer jointly developed Xarelto in partnership with J&J’s Janssen Pharmaceuticals unit, which sells the blood thinner in the U.S.
Xarelto is Bayer’s best-selling drug. In 2018, it generated $4.07 billion in revenue for the company.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
